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ABSTRACT 
We performed exome sequencing in patients from a family of Italian descent with an 
autosomal dominant gastropathy resembling Ménétrier disease, a premalignant disorder of the 
stomach with epithelial hyperplasia and enhanced EGFR signaling due to local overproduction of 
TGF-α. Ménétrier disease is believed to be an acquired disorder but its etiology is unknown. In 
affected patients, we found a missense p.V742G variant in MIB2, a gene regulating NOTCH 
signaling that has not been previously linked to human diseases. The variant segregated with the 
disease in the pedigree, affects a highly conserved amino acid residue, and was predicted to be 
deleterious although it was found with a low frequency in control populations. The purified protein 
carrying the p.V742G variant showed reduced ubiquitination activity in vitro and white blood cells 
from patients exhibited significant reductions of HES1 and NOTCH3 expression reflecting 
alteration of NOTCH signaling. Because mutations of MIB1, the homolog of MIB2, have been 
found in patients with left ventricle non-compaction (LVNC), we screened members of the family 
with Ménétrier-like disease for this cardiac abnormality. Asymptomatic left ventricular 
hypertrabeculation, which is the mildest end of the LVNC spectrum, was detected in two members 
carrying the MIB2 variant. Finally, we identified a MIB2 variant (p.V984L) affecting protein 
stability in an unrelated patient with LVNC. Expression of both MIB2 variants affected NOTCH1 
signaling, proliferation and apoptosis in primary cardiomyocytes. 
In conclusion, we report the first example of left ventricular hypertrabeculation/LVNC with 
germline MIB2 variants resulting in altered NOTCH signaling that might be associated with a 
gastropathy clinically overlapping with Ménétrier disease. 
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TEXT 
Whole exome sequencing (WES) is a powerful tool in identifying disease-associated 
variants in a wide variety of genetic diseases1. In this study, we performed WES on a family of 
Italian descent with multiple members presenting with an autosomal dominant gastropathy with 
Ménétrier-like features2 (Fig. 1A). Ménétrier disease is a premalignant disorder of the stomach 
presenting with gross cerebriform hypertrophy of gastric mucosa confined to the body and fundus 
with sparing of the antrum3; 4. Enhanced epidermal growth factor receptor (EGFR) signaling due to 
local overproduction of transforming growth factor-α (TGF-α) that results in expansion of surface 
mucous cells in the body and fundus of the stomach5-8 has been shown in affected patients3. 
Therefore, patients with Ménétrier disease are treated with Cetuximab, a monoclonal antibody 
blocking EGFR signaling9. Nevertheless, the underlying molecular defect(s) that results in 
upregulation of TGF-α in Ménétrier disease is still unknown and TGF-α is not overexpressed 
elsewhere in the body of individuals with Ménétrier disease3. Familial occurrence of Ménétrier 
disease has been rarely reported10,4,11. Unraveling the molecular defects underlying rare familial 
forms might provide hints to understand the molecular basis of Ménétrier disease. Like classic 
Ménétrier syndrome, the gastric lesions in the family with Ménétrier-like syndrome2 showed EGFR 
overexpression (Fig. 1B). WES was performed on four affected members of the family (subjects 
II.2, II.4, IV.2, and IV.5 of Fig. 1A). Given the autosomal dominant pattern of inheritance, we 
focused on single nucleotide variations and small insertions and deletions (indels) in heterozygous 
state. We selected only heterozygous variants falling within coding regions not predicted to 
generate synonymous amino acid changes, affecting all four samples analyzed, and presenting with 
sufficient depth and quality. Eight single nucleotide substitutions passed this filtering process 
(Table 1). Among these, six were described in ExAC database with frequency >0.01 and were 
discarded. The two remaining variants in nucleoporin-98 (NUP98) and mind-bomb 2 (MIB2) were 
confirmed by Sanger sequencing and analyzed for phenotype segregation among affected family 
members. We observed segregation in all ten affected members with available DNA only for the 
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c.2225T>G (p.V742G) heterozygous variant in MIB2 gene (Fig. 1A). Subject III.3 was 
asymptomatic and never underwent gastric endoscopy but was an obligate carrier having 
transmitted the disease to his child. Asymptomatic subject III.4 who did not carry the MIB2 variant 
was evaluated by gastric endoscopy that failed to show the abnormalities observed in the other 
family members. The p.V742G variant was found with a low frequency of 0.00055 in European 
non-Finnish population and with a cumulative frequency of 0.00147 in control populations (Table 
2). This variant was detected in the homozygous state in two Asian individuals reported in the ExAc 
database. Nevertheless, the variant changes a highly conserved valine into glycine at the amino acid 
position 742 that is predicted to be deleterious by multiple methods (Supplementary Table 1). The 
Val742 is positioned towards C-terminus in a highly conserved ankyrin repeat (a.a. 717-769; Pfam 
ID: PF13637) suggesting that the p.V742G variant might result in structural and/or functional 
effects disturbing the hydrophobic packing between α helices which destabilize the helix-turn-helix 
fold of the ankyrin repeat (Fig. 2A)12; 13. Clustering of disease-related variants in regions of the 
three-dimensional structure is sometimes used as supporting evidence for the pathogenicity14 and 
known cancer-related variants, such as p. A752V (Liver) and p. D775N (Lung), are also positioned 
in this ankyrin repeat, and nearby p.V742G, according to Structure-PPi method15. Another single 
nucleotide variant in MIB2 gene, c.214T>C (p.F72L) was found either in homozygous or 
heterozygous states in all affected family members (Supplementary Fig. 1) and this variant has a 
cumulative frequency of 0.6228 in controls (Table 2). Among the other variants detected by the 
exome, we also found the c.98C>G (p.P33R) variant in TP53 gene that has been reported among the 
polymorphisms associated with the risk of cancer of the stomach16 and gastrointestinal tract17.  
Because MIB1 mutations were recently found to be responsible for left ventricle non-
compaction (LVNC)18, we evaluated 4 family members for this heart defect by cardiac ultrasound, 
even though none of them had cardiac complaints. The cardiac ultrasound followed by cardiac MRI 
revealed in two (III.6 and IV.2) of four (III.2, III.6, IV.2, IV.5) family members carrying the MIB2 
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variant enhanced apical trabeculation of the left ventricle which is consistent with an incomplete 
phenotype of LVNC (Fig. 1A, C).  
We next evaluated a small group of patients with cardiomyopathy and left ventricular 
hypertrabeculation or isolated LNVC who previously underwent extensive clinical testing for a 
panel of 38 cardiomyopathy genes (see Methods) by next generation sequencing (n=7). We 
identified a c.2950G>C (p.V984L) variant in MIB2 gene in a 47 year-old African American woman 
with typical LVNC who presented with symptoms of paresthesia and chest pain. Echocardiogram 
revealed an ejection fraction (EF) of 48% and mild left atrium (LA) and right atrium (RA) dilation 
along with hypertrabeculated left ventricle (LV) consistent with the diagnosis of LVNC (Fig. 1C). 
The cardiac MRI identified increased left ventricular trabeculation with deep intratrabecular 
recesses of the apex extending to the mid LV, with a noncompacted to compacted myocardium ratio 
at the LV apex of 5:1, thus confirming the diagnosis of LVNC (Fig. 1C). In addition, the systolic 
function was found to be only mildly reduced with an EF of 46%, while the LA and RA appeared 
normal in size. There were no apparent valve abnormalities and there was no delayed gadolinium 
enhancement. The electrocardiogram (ECG) showed sinus rhythm with premature supraventricular 
complexes, nonspecific T wave abnormality with a QTc interval of 450 ms (Supplementary Fig. 
2). The patient did not have gastrointestinal complaints. She belongs to a family with several 
siblings and she is the only member who currently has a diagnosis of LVNC. Both maternal and 
paternal ancestry is African American. However, consanguinity was denied. The family history was 
negative for diagnoses of hypertrophic cardiomyopathy (HCM) and/or non-ischemic dilated 
cardiomyopathy (DCM), sudden death or implantable cardioverter defibrillator (ICD) placement, 
although both parents suffered a myocardial infarction consistent with coronary artery disease and 
some of her siblings had unspecified cardiac symptoms. Echocardiogram in the mother did not 
identify any major left ventricular abnormalities. Both parents and other family members were 
unavailable for genetic testing, thus segregation analysis was not possible.  
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The p.V984L variant is not present in EVS while it is reported in ExAC in 1 out 102,118 
alleles (9.8x10-6) (Table 2). The variant changes a valine into leucine at the conserved amino acid 
position 984 but is not predicted to be deleterious by prediction methods (Supplementary Table 1). 
Nevertheless, the variant is predicted to affect the 3D stability of the protein (Supplementary 
Table 1). The Val984 is located in the linker region between two zinc-fingers RING type motifs 
(a.a. 945-987; Pfam ID: PF13920), and in the vicinity of the ligand-binding cysteine residues and 
also the cancer variant p.I979M (Fig. 2B). Moreover, Val984 is conserved in homolog MIB1 
protein and the same region of MIB1 protein was previously found to be affected by a mutation 
responsible for LVNC18.  
To investigate whether the MIB2 variants result in impaired protein function, we performed 
an in vitro functional ubiquitination assay (Fig. 2C and D). MIB2 protein was previously shown to 
undergo auto-ubiquitination19. Purified recombinant MIB2WT, MIB2V742G and MIB2V984L proteins 
were incubated with E1, E2 proteins, and FLAG-ubiquitin to measure auto-ubiquitination activity 
by Western blotting. The protein band detected by the antibody against the ubiquitin-FLAG was 
reduced in the MIB2V742G mutant compared to the wild-type protein. Therefore, MIB2V742G is less 
auto-ubiquitinated compared to the wild-type protein, suggesting a reduced ubiquitin ligase activity. 
In contrast, the MIB2V984L mutant was not found to affect its auto-ubiquitination activity (Fig. 2C, 
D). Nevertheless, the levels of this mutant protein were significantly reduced by Western blotting 
performed with two different antibodies recognizing different protein epitopes in transfected HeLa 
cells (Supplementary Fig. 3), even though no significant differences were observed in the mRNA 
levels of MIB2 and GFP protein levels used as an internal control of transfection efficiency 
(Supplementary Fig. 3). To investigate the degradation rate of MIB2 mutants, HEK293 cells were 
first transfected with Flag-tagged MIB2WT, MIB2V742G or MIB2V984L and then treated with 
cycloheximide (CHX) to block protein synthesis; MG132 was used as control to inhibit proteasomal 
degradation of transfected proteins. Western blot analysis for MIB2 showed significantly reduced 
degradation rate for MIB2V742G compared to the wild-type protein while the MIB2V984L protein 
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could only be detected after MG132 treatment, suggesting rapid proteasomal degradation (Fig. 2E-
F). Transgene expression was confirmed by real time PCR that did not show differences among 
transfected plasmids (Supplementary Fig. 4).  
Previous studies have shown that both MIB1 and MIB2 regulate NOTCH activity20; 21. 
Therefore, we evaluated NOTCH signaling genes in RNA extracted from white blood cells of two 
affected members from pedigree 1 (III.6 and IV.5) that were compared to age- and gender-matched 
controls. Significant reductions of HES1 and NOTCH3 expression were detected in both patients 
while NRARP expression was significantly down-regulated in patient III.6 compared to 
corresponding controls and showed a trend in reduction in patient IV.5 (Fig. 3). Taken together, 
these data show decreased NOTCH signaling in white blood cells carrying the p.V742G variant. 
Blood sample for RNA analysis was not available for the isolated case of LVNC carrying the 
p.V984L variant.  
To investigate the consequence of MIB2 variants on NOTCH signaling, neonatal rat 
cardiomyocytes were infected with adeno-associated viral vectors (AAV6) expressing MIB2V742G, 
MIB2V984L or MIB2WT and were also transfected with a plasmid bearing the luciferase gene under 
the control of an artificial NOTCH1 responsive element containing four repeats of the CBF1 
binding sites22. AAV6 vectors have shown robust and persistent transgene expression in 
cardiomyocytes23. To distinguish specific NOTCH-mediated transactivation effect triggered by the 
transgenes delivered by the AAV6, cardiomyocytes were grown in the presence of a γ-secretase 
inhibitor [DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester)] to inhibit 
endogenous NOTCH1 receptor signaling24. Transcriptional activation of NOTCH regulatory 
elements by either MIB2V742G or MIB2V984L was reduced compared to MIB2WT (Fig. 4A). 
Cardiomyocytes transduced with the vector encoding MIB2V742G also showed decreased vitality 
compared to MIB2WT control; only a trend in reduction of vitality was observed in cells transduced 
with the MIB2V984L (Fig. 4B). To determine whether MIB2 mutants affect cardiomyocyte 
proliferation, incorporation of thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU) was evaluated 
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in cardiomyocytes transduced with AAV6 encoding wild-type or MIB2 variants. MIB2WT increased 
the number EdU-positive and α-actinin-positive cells whereas MIB2V742G variant decreased the 
number of proliferating rat cardiomyocytes (Fig. 4C-D). A trend in reduction of proliferating cells 
was detected in cells transduced with MIB2V984L (Fig. 4C-D). 
We report herein the first example of inherited disorder with left ventricular 
hypertrabeculation/LVNC due to MIB2 mutations altering NOTCH signaling. Patients of a large 
pedigree analyzed herein harboring the p.V742G variant in MIB2 gene also showed clinical features 
of a gastropathy that closely resembles Ménétrier disease2. Within the affected family members 
with Ménétrier-like disease, at least one individual (III.3) carrying the p.V742G variant was free of 
gastric symptoms suggesting incomplete penetrance of the stomach disease. Variable expressivity 
of the gastric phenotype was also observed2. Nevertheless, the low frequency of the p.V742G 
variant in the control population and the rare occurrence of Ménétrier-like syndrome suggest that 
the MIB2 variant is not the only cause for the gastropathy. In addition to MIB2 mutations, other 
genes or environmental factors could be necessary for clinical expression of the gastropathy. The 
affected family members were also found to harbor the polymorphisms p.F72L in MIB2 gene 
p.P33R in TP53 gene. We speculate that the inheritance of the combination of either or both 
polymorphisms with the p.V742G variant might play a role in the expression and severity of the 
gastric phenotype. 
Ménétrier disease has been previously linked to infection with CMV, particularly in 
children25, and Helicobacter pylori3. Interestingly, both CMV and Helicobacter pylori have been 
found to downregulate NOTCH expression26 27. However, it should be noted that no evidence of 
infections by CMV and Helicobacter pylori was detected in the index cases of the pedigree2. 
Nevertheless, additional yet unidentified genetic, epigenetic28 or environmental factor(s) might 
affect NOTCH signaling thus resulting in the expression of the disease. 
NOTCH signaling is critical for cell-fate determination and is involved in maintaining the 
balance between cell proliferation and differentiation29. The gastric epithelium is continuously 
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regenerated by gastric stem cells that give rise to various cell types including parietal cells, chief 
cells, surface mucous cells, mucous neck cells, and enteroendocrine cells. The region in which 
progenitor cells are found is located at the isthmus of the gastric glands. From this region, precursor 
cells give rise to surface mucous cells that move to the luminal surface of the glands, parietal cells 
that move to the base of the glands, and mucous neck cells which also migrate down and further 
differentiate into chief cells. NOTCH signaling is required to maintain the gastric stem cell 
compartment30. Therefore, it is not surprising that alteration of NOTCH signaling in the stomach 
might lead to gastric hypertrophy. Cross-talk between EGFR and NOTCH has been previously 
reported31 and could be responsible for the increased EGFR expression observed in the patients. 
Although some differences exist between Ménétrier-like observed in the family and classic 
Ménétrier disease2, we speculate that NOTCH pathway might also be involved in the pathogenesis 
of Ménétrier syndrome. 
Several genes have been linked to LVNC and they encode proteins involved in cellular 
energy, muscle development, ion channel formation, or components of the muscle filaments32-34. 
Altogether, these defects show that LVNC is caused by at least two final common pathways: a 
primary pathway (such as the sarcomere) and a developmental pathway (such as the NOTCH 
pathway)35; 36. Evidence from mouse developmental studies show that hypertrabeculation results 
from altered regulation of cell proliferation, differentiation, and maturation during the formation of 
the ventricular wall, particularly if the NOTCH signaling pathway is affected37. Inactivation of 
NOTCH pathway genes such as Notch1, Rbpj, or Fkbp1a in mice results in disruption of 
trabeculation of ventricular chamber and spongy myocardial wall38,39; 40. Further support for the role 
of NOTCH pathway in LVNC was confirmed in humans with autosomal dominant LVNC and 
germline mutations in MIB1 gene18. Similarly to MIB2 variants reported herein, two MIB1 
mutations previously found in patients with LVNC also affect the ankyrin repeat and the zinc-finger 
RING type motif18, thus suggesting the important roles of these domains in protein function or 
stability.  
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The diagnosis of LVNC relies on non-invasive imaging studies, usually echocardiography 
and cardiac MRI. However, the diagnostic criteria for both these methods are still debated and are 
currently based on measurements of the ratio of the thickness of the non-compacted layer to that of 
the compacted layer41. Such criteria were present in two patients with left ventricular 
hypertrabeculation/LVNC carrying the p.V742G variant in MIB2 gene. Healthy individuals and 
competitive athletes may fulfill current imaging criteria for diagnosis of LVNC presenting with 
normal left ventricular size and preserved systolic and diastolic functions. This has been considered 
a benign variant39; 42. Therefore, it has been proposed that the extent of myocardial compaction may 
be a continuous spectrum within the population ranging from asymptomatic individuals to end stage 
heart failure. Based on the lack of cardiac complains and altered heart function in the patients with 
p.V742G variant and the very low frequency of MIB2 variant in the population, we argue that at 
least a subgroup of individuals with benign LVNC might harbor MIB2 mutations. It remains to be 
ascertained whether and which additional hits, either genetic or environmental, are needed for the 
development of overt cardiac disease. The identification of a larger number of individuals harboring 
MIB2 mutations will allow understanding the full spectrum of cardiac and gastric phenotype 
associated with mutations in this gene.  
In conclusion, we found that germline MIB2 variants resulting in altered NOTCH signaling 
are associated with a spectrum of left ventricular hypertrabeculation/LVNC and might be associated 
with hypertrophic gastropathy clinically overlapping with Ménétrier disease. 
 
PATIENTS AND METHODS 
Patients 
The clinical findings of the family with inherited gastropathy and LVNC (Fig. 1A) are 
described in greater details elsewhere2. The patient with LVNC (Fig. 1B) was part of a highly 
selected case series of patients with cardiomyopathy and left ventricular hypertrabeculation or 
isolated LVNC. This patient underwent clinical genetic testing for a next generation sequencing 
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panel of 38 genes associated with various forms of cardiomyopathies including ACTC1, ACTN2, 
ANKRD1, CSRP3, DES, EMD, LAMP2, LMNA, MTND1, MTND5, MTND6, MTTD, MTTH, MTTI, 
MTTK, MTTL1, MTTL2, MTTM, MTTQ, MTTS1, MTTS2, MYBPC3, MYH7, NEXN, PLN, RBM20, 
SCN5A, SGCD, TAZ, TCAP, TNNC1, TNNI3, TNNT2, TPMI, TTN, TTR, VCL, ZASP.  
 
Exome sequencing 
 Exome sequencing was performed on DNA samples extracted from peripheral blood of 
four patients in two different sessions. Samples from patients IV.2 e IV.5 were performed by 
hybridization of shotgun fragment libraries to the Agilent SureSelect Human All Exon v1 (Agilent 
Technologies, Santa Clara, CA, USA) in-solution capture assays and libraries were sequenced using 
the SOLiD system v3.5 (Life Technologies, Carlsbad, CA, USA) according manufacturer’s 
instructions. The sequences were analyzed using an automated custom pipeline. Sequencing reads 
were first colour-corrected using SOLiD Accuracy Enhancer Tool (SAET), then mapped to the 
reference genome (UCSC, hg19 build) using the software BioScope v1.3 (Life Technologies) and 
duplicate reads were removed using Picard (http://picard.sourceforge.net). Single nucleotide 
variations (SNV) and in-del mutation calling analyses were carried out using the appropriate 
BioScope calling module: diBayes algorithm with medium stringency settings and the SOLiD 
Small Indel Fragment Tool, respectively. 
Samples from patients II.2 e II.4 were performed by hybridization of shotgun fragment 
libraries to the Illumina TruSeq Exome Enrichment Kit (Illumina inc., San Diego, CA, USA) and 
libraries were sequenced using the HiSeq1000 system (Illumina) according manufacturer’s 
instructions. The sequences were analyzed using an automated custom pipeline also available as 
web resource43. Paired sequencing reads were aligned to the reference genome (UCSC, hg19 build) 
using BWA 44 and post-alignment process and duplicate removal was performed using SAMtools 45 
and Picard. Further processing (local realignment around in-del and base recalibration) and SNV 
and in-del calling were performed with Genome Analysis Toolkit (GATK)46. 
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The called SNV and indel variants produced with both platforms were annotated using 
ANNOVAR 47 with: the relative position in genes using the RefSeq 48 gene model, amino acid 
change, presence in dbSNP (v137) 49 and in known disease-associated databases 50-52, frequency in 
Exome Aggregation Consortium (ExAC) (v0.3), NHLBI Exome Variant Server, 1,000 genomes 
project 53, multiple cross-species conservation 54; 55 and prediction scores of damaging on protein 
activity 56-60. 
The annotated results were then imported into an in-house variation database, also used to 
make comparisons among samples and filter results. The alignments at candidate positions were 
visually inspected using the Integrative Genomics Viewer (IGV) 61. MIB2 mutations were 
confirmed by Sanger sequencing (Primm, Milan, IT). 
 
Computational analysis 
Prediction of deleterious effect of the identified variants was performed by a combined 
approach using: 1) prediction of variant pathogenicity; 2) prediction of protein stability changes; 
and 3) functional annotations that overlap or are in close proximity to the affected residues. Human 
MIB2 (UniProt accession: Q96AX9) is a multi-domain protein with 1070 amino acids whose three-
dimensional (3D) structure has not been determined yet. MIB2 gene codes for 17 protein-coding 
transcripts, according to Ensembl database (http://www.ensembl.org/), therefore in the present 
manuscript the nucleotide and amino acids sequences are numbered according to RefSeq ID 
(NM_080875) and Ensembl protein ID (ENSP00000426103), respectively. Notice that the Ensembl 
protein sequence (ENSP00000426103) differs from the UniProt reference sequence (Q96AX9). 
Only a few 3D models of the human MIB2 are available at ModBase 
(https://modbase.compbio.ucsf.edu/), a repository that collects comparative protein structure 
models. The sequence identity between MIB2 (a.a. 658-772) and a designed ankyrin repeat protein 
whose crystal structure was used as template (PDB ID: 1n0r, chain A, 1.5Å resolution), is 46%, 
well above the threshold of 30% for reliable fold assignment. We next focused on the 3D modeling 
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of the MIB2 region 945-987, which accommodates the missense variant p.V984L and a Zinc-finger 
RING type motif. We submitted the MIB2 sequence to the I-TASSER method 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER) for 3D modeling. The ab initio 3D model 
calculated by I-TASSER shows a 33% sequence identity with the crystal structure of Baculoviral 
cIAP2 RING domain (PDB ID: 3eb5, chain A, 2.0Å resolution). 
To gain insight into the putative functional effects of the MIB2 variants, we mapped 
p.V742G and p.V984L onto 3D models. We also used the dbNSFP v2.8 database62 to obtain the 
damage prediction of identified missense variants by PolyPhen-2, SIFT, MutationAssessor, SVM, 
and VEST3. For the identified variants, protein stability calculations were performed using 
CUPSAT (http://cupsat.tu-bs.de), I-Mutant 2.0 (http://folding.biofold.org/i-mutant/i-
mutant2.0.html), and PoPMuSiC (http://dezyme.com). Functional annotations (e.g., ligand-binding 
residues, protein domains, reported variants in COSMIC database, UniProt annotations for missense 
variants that overlap the mutation position, residues located in close physical proximity or that 
affect protein interaction surfaces) were retrieved with the Structure-PPi method available at 
http://structureppi.bioinfo.cnio.es/Structure15. 
 
In vitro ubiquitination assay 
Full-length human MIB2 cDNA in pCMV-Sport6 backbone was purchased from Open 
Biosystems (GE Healthcare, Pittsburgh, PA, USA). The MIB2 mutant constructs (MIB2_V742G 
and MIB2_V984L) were generated using QuikChange II XL-site-directed mutagenesis (Agilent 
Technologies), according to manufacturer’s instructions. The cDNAs which encoded full length 
MIB2 were subcloned into a pGEX-4T-3 GST expression vector (GE Healthcare). Cloned cDNA 
full-length sequences were confirming by Sanger sequencing (Primm). GST-tagged MIB2 
constructs were expressed in Rosetta (DE3) cells using isopropyl-1-thio-β-D-galactopyranoside 
(IPTG) (Sigma-Aldrich). Recombinant proteins were affinity-purified using glutathione Sepharose 
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4B resin (GE Healthcare). Purified proteins were then analyzed by sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) and Coomassie Brillant Blue. 
In vitro ubiquitination assay was performed according to a modified version of methods 
previously reported20. Recombinant ubiquitin-activating enzyme E1 (Sigma-Aldrich, St. Louis, 
MO, USA) and GST-fused MIB2 proteins were mixed into a reaction mixture containing 50 
mmol/L Tris-HCl pH 7.4, 5 mmol/L MgCl2, 4 mmol/L ATP, 0.5 mmol/L dithiothreitol, 15 µg of 
FLAG-ubiquitin (Sigma-Aldrich), and incubated in equimolar amounts human His-tagged UbcH5b 
(E2) (BioVision, Milpitas, CA, USA) at 30°C for 4 hours. Proteins were then subjected to SDS 
PAGE under reducing conditions and detected by western blotting using primary antibodies to the 
FLAG tag (Sigma-Aldrich) or to MIB2 (Novus Biological,  Littleton, CO, USA) protein. ECL anti-
mouse and anti-rabbit HRP secondary antibodies (GE Healthcare) were used for FLAG and MIB2, 
respectively. Analysis of band intensities was performed using Quantity One basic software (Bio-
Rad Laboratories, Hercules, CA, USA). 
 
Expression of MIB2 mutants  
HeLa cells (ATCC) were co-transfected with pCMV-GFP and plasmid expressing either 
wild-type, MIB2 mutants, or p3xFLAG-CMV-14 (Sigma-Aldrich) with Lipofectamine2000 (Life 
Technologies) according to manufacturer’s instructions. 18 hours post-transfection, proteins and 
RNA were extracted in either RIPA buffer or with RNeasy kit (Qiagen). Proteins were analyzed by 
western blotting using rabbit anti-MIB2 (Novus Biological), mouse anti-MIB2 (Abcam, Cambridge, 
UK), and anti-GFP (Life Technologies). Anti-GAPDH (Santa Cruz Biotechnology) was used for 
normalization. ECL anti-rabbit or anti-mouse HRP to MIB2, and ECL anti-mouse HRP to GFP and 
GAPDH were used as secondary antibodies (GE Healthcare). RNA was reverse transcribed using a 
first-strand complementary deoxyribonucleic acid kit with random primers according to 
manufacturer’s protocol (Life technologies, Grand Island, NY, USA). The qPCR reactions were 
performed using Roche Light Cycler 480 system (Roche, Indianapolis, IN, USA). PCR reactions 
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were performed with SYBR Green Master Mix (Roche). PCR conditions were as follows: pre-
heating, 5 minutes at 95°C; 40 cycles of 15 seconds at 95°C, 15 seconds at 60°C, and 25 seconds at 
72°C. Quantification results were expressed in terms of cycle threshold (Ct). For the expression 
analysis GUSB and HPRT1 housekeeping genes were used as endogenous controls (reference 
markers) using LightCycler 480 software v1.5. Differences between mean Ct values of tested genes 
and those of the reference gene were calculated as ΔCt gene = Ct gene - Ct reference. WT1 sample 
was used as calibrator and relative fold increase in expression levels was determined as E-ΔΔCt, E 
being primer efficiency. The Ct values were averaged for each technical duplicate. Primers to MIB2 
and GFP are reported in Supplementary Table 2. Analysis of protein stability 
MIB2wt-Flag, MIB2V742G-Flag and MIB2V984L-Flag were transfected in Hek 293 cells 
using a standard Calcium Phosphate protocol. 24 hrs after transfection, the medium was 
supplemented with 10 µg/ml cycloheximide (CHX; Calbiochem) for 1, 2, 3 and 4 hrs prior to cell 
lysis in RIPA Buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.5% NaDoc, 
1% Triton X-100, and 0.1% SDS) supplemented with 90 μg/ml PMSF, 1 mM NaVO4 (all from 
Sigma) and proteases inhibitors (Roche). The proteasome inhibitor MG132 (Calbiochem) was 
supplemented at a concentration of 10 µM for 4 hr. After sonication and pre-clearing, protein lysate 
concentration was determined by Bradford Assay (BIORAD). Equal amounts of protein were 
resolved on 8% SDS-PAGE mini-gels and transferred to nitrocellulose membranes (GE 
Healthcare). Western Blotting was performed as described above, using a monoclonal Flag-Tag 
antibody (1:2000, Pierce, Thermo Scientific). 
 
NOTCH gene expression in white blood cells 
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White blood cells were isolated from peripheral blood using Lymphocyte Separation 
Medium (Lonza, Basel, Switzerland) from patients III.6 and IV.5, and from age matched healthy 
controls. Total RNA was extracted from primary cultured fibroblasts using RNeasy kit (Qiagen, 
Hilden, Germany) according to supplier’s instructions. RNA was reverse transcribed and amplified 
by qPCR reaction as reported above. Primers were described in the Supplementary table 2. 
 
rAAV vectors 
Recombinant AAV vectors were prepared by the AAV Vector Unit at the International 
Centre for Genetic Engineering and Biotechnology Trieste as described previously63. In brief, 
infectious AAV6 vector particles were generated in HEK293 cells by cotransfecting each vector 
plasmid (pAAV-MIB2WT, - MIB2V742G, - MIB2V984L, vector and pAAV-MCS) together with the 
packaging plasmid (pAAV6-264 and helper plasmid (pHELPER; Stratagene), expressing AAV and 
adenovirus helper functions, respectively. Viral stocks were obtained by CsCl2 gradient 
centrifugation; rAAV titers, determined by measuring the copy number of viral genomes in pooled, 
dialyzed gradient fractions, as described previously 65, were in the range of 1x1010 to 1x1013 vg/ml. 
 
Rat primary cardiomyocytes 
Animal care and treatment were performed following the Institutional Guidelines in 
compliance to National and International laws and policies. Wistar rats were purchased from 
Charles River Laboratories Italia and maintained under controlled environmental conditions. 
Ventricular cardiomyocytes from neonatal rats were isolated as previously described24. In brief, 
ventricles from neonatal rats (post-natal day 1) were separated from the atria, cut into pieces and 
dissociated in CBFHH (calcium and bicarbonate-free Hanks with Hepes) buffer containing 2 mg/ml 
of trypsin (BD Difco) and 20 µg/ml of DNase II (Sigma) under constant stirring. Digestion was 
performed at room temperature in eight-to-ten 10-min steps, collecting the supernatant after each 
step. The supernatants were centrifuged to separate the cells which were then resuspended in 
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Dulbecco’s modified Eagle medium 4.5 g/L glucose (DMEM, Life Technologies) supplemented 
with 5% FBS, 20 µg/ml vitamin B12 (Sigma), 100 U/ml penicillin and 100 µg/ml of streptomycin 
(Sigma). The collected cells were filtered through a cell strainer (40 µm, BD Falcon), and then 
seeded onto uncoated 100-mm plastic dishes for 2 hours at 37°C in 5% CO2 and humidified 
atmosphere. The supernatant composed mostly of cardiomyocytes was then collected and plated. 
Cultures of neonatal rat ventricular cardiomyocytes prepared by this procedure yielded consistently 
a purity >90%. In the experiments with AAV-mediated gene transfer, neonatal rat cardiomyocytes 
were infected immediately after isolation using 1x105 viral genomes (vg)/cell. Twelve hours later, 
the culture medium was changed and cells were subjected to the different treatments and subsequent 
analyses. 
 
Functional studies in primary cardiomyocytes 
To detect Notch1 activity under different experimental conditions, neonatal cardiomyocytes 
were seeded onto 96-well primary cells culture plates (1.5 x104 cells per well) and transduced with 
AAV6-MIB2WT, AAV6- MIB2V742G, AAV6- MIB2V984L, or an empty AAV6-MCS vector 
(moi=1x105 vg/cell). The day after the infection, cardiomyocytes were co-transfected with 0.5 μg of 
4XCBF1-Luc reporter plasmid and 0.01 μg pRL-Renilla (which was used as an efficiency control) 
by using Lipofectamine 2000 transfection reagent (Invitrogen). After 6 hrs of incubation, medium 
was removed and cells were fed in complete medium for 8 hrs in DMSO (control) or GSI 
containing medium [DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl 
ester)-20µM] prior to lysis in PLB buffer (Promega). Firefly luciferase activity was corrected for 
the transfection efficiency by using the control Renilla luciferase activity in each sample. Firefly 
and Renilla luciferase activities were assayed with the Dual-luciferase assay kit (Promega). 
Cardiomyocyte proliferation was analyzed 4 days after their isolation. Cells transduced with 
either AAV6-MIB2WT, or AAV6- MIB2V742G, or AAV6- MIB2V984L, vector (moi=1x105 vg/cell) 
were grown in culture medium supplemented with 5 µM 5-ethynyl-2’-deoxyuridine (EdU, Life 
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Technologies) for 8 hrs. Cells were fixed with 4% paraformaldehyde for 10 min, permeabilized 
with 0.1% Triton X-100 in phosphate buffered saline (PBS) for 10 min, followed by 1 hr blocking 
in 2% BSA (Roche) in PBS. Cells were then stained over night at 4°C with the mouse anti α-
sarcomeric actinin (EA-53), 1:100 (AbCam). Cells were washed with PBS and incubated for 1 hr 
with the secondary antibodies goat anti-mouse conjugated to Alexa Fluor 488. All washes were in 
PBS 0.2% Tween 20. Cells were further processed using the Click-IT EdU 555 Imaging kit to 
reveal EdU incorporation, according to the manufacturer’s instructions, and stained with Hoechst 
33342 (Life Technologies). 
Image acquisition was performed using an ImageXpress Micro automated high-content 
screening fluorescence microscope at 10X magnification; a total of 16 images were acquired per 
wavelength, well and replicate, corresponding to approximately 2,500 cells analyzed per condition 
and replicate. Image analysis was performed using the Multi-Wavelenght Cell Scoring application 
module implemented in MetaXpress software (Molecular Devices). In all quantifications, 
cardiomyocytes were distinguished from other cells present in the primary cultures by their 
positivity for sarcomeric a-actinin. Images were acquired at room temperature with a DMLB 
upright fluorescence microscope (Leica) equipped with a charge-coupled device camera 
(CoolSNAP CF; Roper Scientific) using MetaView 4.6 quantitative analysis software (MDS 
Analytical Technologies). Within each experiment, instrument settings were kept constant. 
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FIGURE LEGENDS 
Figure 1. (A) Pedigree of the family with inherited gastropathy and/or LVNC. (C) EGFR staining 
in gastric specimens from two affected individuals from pedigree and a control (Ctrl). (D) Cardiac 
ultrasound and MRI of patients with LVNC from the one subject of the pedigree harboring the 
p.V742G variants (subject IV.2) and the isolated case with the p.V984L variant. 
 
Figure 2. (A and B) Mapping of MIB2 mutations onto the 3D models of Ankyrin-repeat and Zinc 
finger C3HC4 or RING-type motif. (C and D) Western blotting with antibody against the 
ubiquitinated FLAG after incubation of purified wild-type and mutated MIB2 proteins with E1, E2 
proteins, and FLAG-Ubiquitin. The quantitation of the intensities of protein bands corresponding to 
ubiquitinated FLAG normalized for MIB2 protein band are shown in D. (E) Decreased stability of 
MIB2V984L mutant in transfected primary rat cardiomyocytes. Relative quantification of the amounts 
of MIB2WT, MIB2V742G and MIB2V984L proteins in HEK293 cells incubated with cycloheximide 
(CHX). In the graph, the amount of MIB2 was set at 100% in samples maintained 4 hours in the 
presence of 10 µM proteasome inhibitor MG132. Results are expressed as average ± SD of three 
separate experiments. *p<0.05. 
 
Figure 3. Expression of NOTCH signaling genes in blood lymphocytes of two affected members 
from the pedigree (III.6 and IV.5) compared to age- and gender-matched controls. Average ± SEM 
are shown. 
 
Figure 4. (A) Notch signaling activity measured by 4XCBF1-Luc reporter assay. Primary rat 
cardiomyocytes were transfected with 4XCBF1 firefly luciferase reporter and renilla-luciferase 
reporter for normalization. DAPT treatment reduced 4XCBF1-luciferase reporter activation and was 
used as a specific transactivation control. (B) An ATP-Lite assay and proliferation assay (C-D) on 
freshly isolated rat neonatal cardiomyocytes transduced with AAV6 vectors encoding MIB2WT, 
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MIB2V742G, or MIB2V984L (m.o.i. = 1x105 vg/cell). Representative images of at least 5 separate 
experiments of EdU+ cardiomyocytes after AAV-mediated gene transfer are shown in C. Green, α-
actinin; red, EdU; blue, DNA (DAPI). (D) Quantification of the total number of α-actinin+/EdU+ 
cells (proliferating cardiomyocytes) after 4 days of culture. Results are representative of at least 
three independent experiments. Mean±SD is shown. *, p<0.05; **, p<0.01. 
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Table 1. Variants detected by exome sequencing 
Gene Refseq Variation  Frequency (ExAC) 
NUP98 NM_016320 c.4573G>A (p.A1525T) Not reported 
MIB2 NM_080875 c.2225T>G (p.V742G) 0.0015 (172/116,536 alleles) 
SLC10A2 NM_000452 c.475G>A (p.V159I) 0.01795 (2,178/121,346 alleles) 
SIDT1 NM_017699 c.232G>A (p.V78M) 0.04059 (4,920/121,220 alleles) 
SPICE1 NM_144718 c.823C>G (p.L275V) 0.04793 (5,799/120,984 alleles) 
ZNF781 NM_152605 c.290C>T (p.T97M) 0.05046 (6,125/121,374 alleles) 
KCNJ12 NM_001194958 c.517G>A (p.D173N) 0.4731 (53,101/112,234 alleles) 
GPRIN2 NM_014696 c.298A>C (p.T100P) 0.4838 (57,014/117,836 alleles) 
 
 
Table 2. Frequency of MIB2 variants in human genome variant databases  
Database 
Frequency 
c.214T>C (p.F72L) 
rs7418389  
c.2225T>G (p.V742G) 
rs7418389  
c.2950G>C (p.V984L) 
ExAC 
0.6228  
(61,204/98,272 alleles) 
0.0015 
(172/116,536 alleles) 
9.8x10-6 
(1/102,118 alleles) 
EVS 
0,6709 
(8,086/12,056 alleles) 
Not reported Not reported 
1000genomes 
0.477 
(2,389/5,008 alleles) 
0.003  
(14/ 4,994 alleles) 
Not reported 
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SUPPLEMENTARY ONLINE MATERIAL 
 
Supplementary Table 1. In silico predictions of pathogenicity of MIB2 mutations. 
 c.2225T>G (p.V742G) c.2950G>C (p.V984L) 
Classification Method Score Prediction Score Prediction 
Sequence-
based 
methods 
Polyphen-2 0.998 probably 
damaging 
0.005 Neutral 
SIFT 0.02 damaging 0.42 Neutral 
Mutation-
Assessor 
3.655 functional 
Impact high 
0.585 Neutral 
SVM 0.22 Deleterious -0.979 Neutral 
VEST3 0.89 Deleterious 0.174 Neutral 
Structure-
based 
methods 
 ΔΔG 
(kcal/mol) 
 ΔΔG 
(kcal/mol) 
 
I-Mutant 2.0 -2.69 Decrease 3D 
stability 
-0.7 Decrease 3D 
stability 
PoPMuSiC 2.57 Decrease 3D 
stability 
0.49 Decrease 3D 
stability 
CUPSAT -8.30 Decrease 3D 
stability 
0.86 Increase 3D 
stability 
 
Supplementary table 2. Real-time PCR primers 
Primer name Sequence 
DTX-for 5’-ACGAGAAAGGCCGGAAGGT-3’ 
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DTX-rev 5’-GGTGTTGGACGTGCCGATAG-3’ 
HES1-for 5’-CCTGTCATCCCCGTCTACAC-3’ 
HES1-rev 5’-CACATGGAGTCCGCCGTAA-3’ 
NOTCH3-for 5’-CGTGGCTTCTTTCTACTGTGC-3’ 
NOTCH3-rev 5’-CGTTCACCGGATTTGTGTCAC-3’ 
NRARP-for 5’-TCAACGTGAACTCGTTCGGG-3’ 
NRARP-rev 5’-ACTTCGCCTTGGTGATGAGAT-3’ 
HEY-for 5’-GTTCGGCTCTAGGTTCCATGT-3’ 
HEY-rev 5’-CGTCGGCGCTTCTCAATTATTC-3’ 
GUSB-for 5’-CAACGAGCCTGCGTCCCACC-3’ 
GUSB-rev 5’-ACGGAGCCCCCTTGTCTGCT-3’ 
HPRT1-for 5’-TGGCGTCGTGATTAGTGATG-3’ 
HPRT1-rev 5’-AACACCCTTTCCAAATCCTCAG-3’ 
 
Supplementary Figure 1. Segregation of the p.P33R polymorphism in TP53 gene in family with 
LNVC and inherited gastropathy.   
 
Supplementary Figure 2. Electrocardiogram (EKG) of the non-familiar case with LVNC showing 
sinus rhythm with premature supraventricular complexes, nonspecific T wave abnormality with a 
QTc interval of 450 ms. 
 
Supplementary Figure 3. (A) Western blotting with two different antibodies recognizing different 
epitopes in protein extracts of HeLa cells co-transfected with plasmids expressing the wild-type or 
mutant MIB2 proteins and a plasmid expressing GFP, as an internal control of transfection 
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efficiency. (B) Real time PCR levels of MIB2 in HeLa cells co-transfected with plasmids 
expressing the wild-type or mutant MIB2 proteins. 
 
Supplementary Figure 4. Expression levels of MIB2WT, MIB2V742G, or MIB2V984L in 
cardiomyocytes transduced with AAV6.  
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